SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2

• Leyun Wu,
• Liping Zhou,
• Mengxia Mo,
• Tingting Liu,
• Chengkun Wu,
• Chunye Gong,
• Kai Lu,
• Likun Gong,
• Weiliang Zhu,
• Zhijian Xu

Affiliations

Leyun Wu

CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Liping Zhou

CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Mengxia Mo

College of Computer Science and Technology, National University of Defense Technology

Tingting Liu

Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Chengkun Wu

College of Computer Science and Technology, National University of Defense Technology

Chunye Gong

College of Computer Science and Technology, National University of Defense Technology

Kai Lu

College of Computer Science and Technology, National University of Defense Technology

Likun Gong

Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Weiliang Zhu

CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Zhijian Xu

CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences